Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Surrozen, Inc.NASDAQ: SRZN

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.11M rose 152.4% year over year, ahead of the +30.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 110.1% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.

Context

  • Stock-based compensation amounted to 110.3% of revenue in FY2025, up 71.7 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +152.4% holds above the trailing-twelve-month pace of +30.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.11M+110.1% QoQ
Last fiscal yearDec 2025
$3.84M-6.8% YoY
LTMMar 2026
$5.11M+30.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+152.4%——
1 year-6.8%——
3-year CAGR-5.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
3.84M USD
Year-over-year change
-6.8%
4-year CAGR
+13.4%

Stock-Based Compensation vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's LTM Mar 2026 stock-based compensation of $5.11M is the 4th largest of the 8 companies compared; the peer median is $4.63M.
  • Its year-over-year change of +30.3% is the highest of 8, against a peer median of -42.1%.
  • Stock-based compensation amounts to 68.1% of revenue for SRZN, versus a peer median of 33.0%.
SRZN Competitors Peer median
Stock-Based Compensation for SRZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SEERSeer, Inc.LTM Mar 2026$12.88M -49.1%-22.9%85.6%
AGENAgenus Inc.LTM Mar 2026$10.29M -14.6%-1.8%8.3%
TILInstil Bio, Inc.LTM Mar 2026$6.18M -61.9%-34.1%—
SRZNSurrozen, Inc.LTM Mar 2026$5.11M +30.3%-5.3%68.1%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$4.63M -43.5%+57.4%—
IRDOpus Genetics, Inc.LTM Mar 2026$3.95M +20.1%+23.4%33.0%
IMMXImmix Biopharma, Inc.LTM Mar 2026$2.15M -27.0%+57.6%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$1.83M -42.1%-16.4%—
Peer median (excluding SRZN) $4.63M-42.1%-1.8%33.0%

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(54.65M)(36M)(43.04M)(63.56M)(242.03M)
Depreciation & Amortization2.07M1.96M1.91M1.44M537K
Deferred Income Tax00000
Stock-Based Compensation2.32M4.52M4.37M4.11M3.84M
Change in Working Capital(221K)(8.42M)(3.93M)(836K)3.15M
Accounts Receivables0(1.98M)0(502K)2.33M
Inventory00000
Accounts Payables857K(2.04M)(133K)(228K)142K
Other Working Capital(1.08M)(4.4M)(3.8M)(106K)678K
Other Non-Cash Items1.67M(6.2M)325K41.22M204.26M
Operating Cash Flow(48.81M)(44.15M)(40.36M)(17.63M)(30.24M)
Capital Expenditures(1.27M)(728K)(398K)(26K)(128K)
Acquisitions (Net)0(39.04M)000
Purchases of Investments(91.74M)(29.6M)(28.04M)00
Sales of Investments15.3M68.64M80.17M00
Other Investing Activities039.04M000
Investing Cash Flow(77.71M)38.31M51.72M(26K)(128K)
Debt Repayment00000
Common Stock Issued124.22M42K280K16.04M85.05M
Common Stock Repurchased0(2.61M)(4K)00
Dividends Paid00000
Other Financing Activities410K(85K)280K133K0
Financing Cash Flow124.63M(2.57M)276K16.18M85.05M
Effect of Forex Changes00000
Net Change in Cash(1.89M)(8.4M)11.64M(1.48M)54.68M
Free Cash Flow(50.08M)(44.87M)(40.76M)(17.65M)(30.37M)

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.